Posted: 26 Jun 2019 08:00 PM PDT
We knew it would be back.
It was never dead, though perhaps forgotten by some (never us), but OTC Monograph Reform is back in the public eye again. Lawmakers appear to be taking to heart CDER Director Janet Woodcock’s remarks last week in which she urged the adoption of reforms to the monograph system. On June 24, 2019, a bipartisan group of lawmakers introduced H.R. 3443 to enact the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019, and it was referred to the House Committee on Energy and Commerce. The text of the bill can be found here.
As readers of this blog may recall, FDA has been exploring OTC Monograph Reform and its associated user fees for several years, formally beginning with a public meeting on the subject in June of 2016, which we blogged about here. Remarkable in its bipartisan appeal and support, legislation emerged that seemed destined for passage. However, it stalled over differences in the House and Senate bills on the proposed length of time for marketing exclusivity afforded for certain innovations. That issue was resolved, but it wasn’t the right time for this legislation. Due, at least in part, to complications caused by the federal government shut down, it was still not (yet) to be at the end of 2018. Earlier this year, monograph reform was included in H.R. 269 (the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019) which was passed by the House. Senate leadership concluded a separate bill was not necessary because the provisions had been agreed to by both chambers and it placed the bill on the Senate Legislative Calendar under General Orders where it remains.
The newly introduced H.R. 3443 contains the same language as the monograph section of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 introduced as H.R. 269. Among other things, it:
It was never dead, though perhaps forgotten by some (never us), but OTC Monograph Reform is back in the public eye again. Lawmakers appear to be taking to heart CDER Director Janet Woodcock’s remarks last week in which she urged the adoption of reforms to the monograph system. On June 24, 2019, a bipartisan group of lawmakers introduced H.R. 3443 to enact the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019, and it was referred to the House Committee on Energy and Commerce. The text of the bill can be found here.
As readers of this blog may recall, FDA has been exploring OTC Monograph Reform and its associated user fees for several years, formally beginning with a public meeting on the subject in June of 2016, which we blogged about here. Remarkable in its bipartisan appeal and support, legislation emerged that seemed destined for passage. However, it stalled over differences in the House and Senate bills on the proposed length of time for marketing exclusivity afforded for certain innovations. That issue was resolved, but it wasn’t the right time for this legislation. Due, at least in part, to complications caused by the federal government shut down, it was still not (yet) to be at the end of 2018. Earlier this year, monograph reform was included in H.R. 269 (the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019) which was passed by the House. Senate leadership concluded a separate bill was not necessary because the provisions had been agreed to by both chambers and it placed the bill on the Senate Legislative Calendar under General Orders where it remains.
The newly introduced H.R. 3443 contains the same language as the monograph section of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 introduced as H.R. 269. Among other things, it:
- changes the rulemaking process currently used to establish and modify monographs to what is hoped to be a more efficient order process
- addresses the status of products currently marketed under tentative final monographs
- allows for innovation beyond the constraints of the current system
- provides for marketing exclusivity for certain innovations
- provides FDA with more tools in the event of an emerging safety issue
- provides for user fees which will come with timeline goals for FDA actions.
.png)
No hay comentarios:
Publicar un comentario